Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are anti-obesity drugs that were recently shown to be effective in reducing body weight and ameliorating cardiovascular outcomes in patients with overweight or obesity [51]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.